E1.Goodman AD, Brown TR, Edwards KR, Et Al. a Phase 3 Trial of Extended Release Oral

e-References

e1.Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol2010;68:494-502.

e2.Goodman AD, Bethoux F, Brown TR, et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. MultScler2015;21:1322-1331.

e3.Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. TherAdvNeurolDisord2014;7:97-113.

e4.Zorner B, Filli L, Reuter K, et al. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. MultScler 2016.

e5.Schniepp R, Jakl V, Wuehr M, et al. Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report. MultScler2013;19:506-508.

e6.Schniepp R, Wuehr M, Ackl N, et al. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol2011;258:1708-1711.

e7.Schniepp R, Wuehr M, Neuhaeusser M, et al. 4-aminopyridine and cerebellar gait: a retrospective case series. J Neurol2012;259:2491-2493.

e8.Giordano I, Bogdanow M, Jacobi H, et al. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J Neurol2013;260:2175-2176.

e9.McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. The New England journal of medicine 1989;321:1567-1571.

e10.Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-607.

e11.Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009;40:795-800.

e12.Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. Amifampridine phosphate (Firdapse((R)) ) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 2016;53:717-725.

e13.Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. ClinPharmacolTher2009;86:44-48.

e14.Lundh H, Nilsson O, Rosen I. Novel drug of choice in Eaton-Lambert syndrome. J NeurolNeurosurg Psychiatry 1983;46:684-685.

e15.Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J NeurolNeurosurg Psychiatry 1991;54:1069-1072.

e16.Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J ClinOncol2011;29:902-908.

e17.Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. The New England journal of medicine 1995;332:1467-1474.

e18.Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol2011;10:1098-1107.

e19.Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J NeurolSci1997;147:35-42.

e20.Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002;59:1773-1775.

e21.Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011:CD003279.

e22. (EMA) EMA. Summary of product characteristics - Firdapse [online]. Accessed 04.08.

e23. (EMA) EMA. Summary of product characteristics - Fampyra [online]. Accessed 04.08.

e24.Dutia MB. Mechanisms of vestibular compensation: recent advances. CurrOpinOtolaryngol Head Neck Surg2010;18:420-424.

e25.Beck R, Gunther L, Xiong G, et al. The mixed blessing of treating symptoms in acute vestibular failure--evidence from a 4-aminopyridine experiment. ExpNeurol2014;261:638-645.

e26.Strupp M, Feil K, Bardins S, Waidelich R. 4-aminopyridine improves lower urinary tract symptoms in a patient with benign prostatic hyperplasia and downbeat nystagmus syndrome. IntNeurourol J 2014;18:221-225.

e27.Laskey W, Schondorf R, Polosa C. Effects of 4-aminopyridine on sympathetic preganglionic neuron activity. J AutonNervSyst1984;11:201-206.

e28.Luca CC, Singer C. 4-aminopyridine improves freezing of gait in Parkinson's disease. J Neurol2013;260:2662-2664.

e29.DeForge D, Nymark J, Lemaire E, et al. Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal Cord 2004;42:674-685.

e30.Segal JL, Thompson JF, Tayek JA. Effects of long-term 4-aminopyridine therapy on glucose tolerance and glucokinetics in patients with spinal cord injury. Pharmacotherapy 2007;27:789-792.

e31.van der Bruggen MA, Huisman HB, Beckerman H, Bertelsmann FW, Polman CH, Lankhorst GJ. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol2001;248:665-671.

e32.Bergin PS, Miller DH, Hirsch NP, Murray NM. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol1993;34:406-409.

e33.Leussink VI, Stettner M, Warnke C, Hartung HP. Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. J PeripherNervSyst2016;21:85-87.

e34.Horton L, Conger A, Conger D, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology 2013;80:1862-1866.

e35.avin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. J NeurolSci2016;360:102-109.

e36.Friggeri A, Marcon F, Marciniak S, et al. 3,4-Diaminopyridine may improve neuromuscular block during botulism. Crit Care 2013;17:449.

e37.Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. ClinNeurolNeurosurg2015;139:35-40.

e38.Aisen ML, Sevilla D, Edelstein L, Blass J. A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit. J NeurolSci1996;138:93-96.

e39.Mainero C, Inghilleri M, Pantano P, et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology 2004;62:2044-2050.